Evidence map›Paper›PMID 22322095›Full record

ArticleMolecular & cellular proteomics : MCP2012

The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways.

Marcus L Hastie, Madeleine J Headlam, Nirav B Patel, Alexander A Bukreyev, Ursula J Buchholz, Keyur A Dave, Emma L Norris, Cassandra L Wright, Kirsten M Spann, Peter L Collins and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Marcus L HastieProtein Discovery Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia.
Madeleine J Headlam
Nirav B Patel
Alexander A Bukreyev
Ursula J Buchholz
Keyur A Dave
Emma L Norris
Cassandra L Wright
Kirsten M Spann
Peter L Collins
Jeffrey J Gorman
QIMR Berghofer Medical Research Institute · AUNational Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USUniversity of Queensland · AU

Funding

Laboratory Studies of Human Respiratory Syncytial Virus and Other PneumovirusesZIAAI000372 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BUCHHOLZ, URSULA · 2009 to 2025
$21.8M
Intramural NIH HHS
6 · The paper itself

Abstract

Respiratory syncytial viruses encode a nonstructural protein (NS1) that interferes with type I and III interferon and other antiviral responses. Proteomic studies were conducted on human A549 type II alveolar epithelial cells and type I interferon-deficient Vero cells (African green monkey kidney cells) infected with wild-type and NS1-deficient clones of human respiratory syncytial virus to identify other potential pathway and molecular targets of NS1 interference. These analyses included two-dimensional differential gel electrophoresis and quantitative Western blotting. Surprisingly, NS1 was found to suppress the induction of manganese superoxide dismutase (SOD2) expression in A549 cells and to a much lesser degree Vero cells in response to infection. Because SOD2 is not directly inducible by type I interferons, it served as a marker to probe the impact of NS1 on signaling of other cytokines known to induce SOD2 expression and/or indirect effects of type I interferon signaling. Deductive analysis of results obtained from cell infection and cytokine stimulation studies indicated that interferon-γ signaling was a potential target of NS1, possibly as a result of modulation of STAT1 levels. However, this was not sufficient to explain the magnitude of the impact of NS1 on SOD2 induction in A549 cells. Vero cell infection experiments indicated that NS1 targeted a component of the type I interferon response that does not directly induce SOD2 expression but is required to induce another initiator of SOD2 expression. STAT2 was ruled out as a target of NS1 interference using quantitative Western blot analysis of infected A549 cells, but data were obtained to indicate that STAT1 was one of a number of potential targets of NS1. A label-free mass spectrometry-based quantitative approach is proposed as a means of more definitive identification of NS1 targets.

Indexed as

AnimalsCatalaseCell Line, TumorChlorocebus aethiopsCluster AnalysisGene Expression RegulationHost-Pathogen InteractionsHumansInterferon-gammaInterferon Type IIntracellular Signaling Peptides and ProteinsOxidative StressProteomeRespiratory Syncytial Virus, HumanSignal TransductionSTAT1 Transcription FactorCatalaseIFIT3 protein, humanInterferon-gammaInterferon Type IIntracellular Signaling Peptides and ProteinsProteomeSTAT1 protein, humanSTAT1 Transcription FactorSTAT2 protein, humanSTAT2 Transcription FactorSuperoxide DismutaseSuperoxide Dismutase 2Viral Nonstructural Proteins

Identifiers

PMID22322095
PMCPMC3418853
OpenAlexW2134001115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.